TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27790789

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg and sofosbuvir 400 mg daily for 8 weeks (Group A1, n=20)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group A2, n=20)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group B, n=23)
Number of subjects: 63
Study: 25985992

Group type: EXPERIMENTAL
Intervention: Mass Testing and Treatment Intervention (MTAT) using rapid diagnostic tests (RDTs) and artemether-lumefantrine (AL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Mass Testing and Treatment Intervention (Standard of Care)
Number of subjects: 0
Study: 24836471

Group type: EXPERIMENTAL
Intervention: Capnography monitoring combined with standard respiratory monitoring
Number of subjects: 427

Group type: COMPARATOR
Intervention: Standard respiratory monitoring (standard care)
Number of subjects: 427
Study: 22594858

Group type: EXPERIMENTAL
Intervention: Thermotherapy (single session at 50°C)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Meglumine antimoniate (20 mg Sb5/kg weight/day for 20 days)
Number of subjects: 273
Study: 19281114

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (RelyX Unicem)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multistep adhesive (Syntac) with Variolink II low viscosity (Control)
Number of subjects: 30
Study: 17223022

Group type: EXPERIMENTAL
Intervention: Bioadhesive formulations (LM-5, LM-12, chitosan G210) delivered using a nasal drop device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-bioadhesive control delivered with the same nasal drop device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pectin formulation administered with a nasal spray system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioadhesive formulations
Number of subjects: 0
Study: 15156901

Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 736

Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Self-assessment visual analogical score
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Control visits
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Health resources used
Number of subjects: 736
Study: 12401244

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g bolus over 15 min, followed by 17 g infusion over 24 h)
Number of subjects: 6213

Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 6213
Study: 9649951

Group type: EXPERIMENTAL
Intervention: Insulin + Glipizide (I + G)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Insulin + Placebo (I + P)
Number of subjects: 37
Study: 7484520

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium combined with Imipramine
Number of subjects: 78
Study: 1962618

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 466

Group type: COMPARATOR
Intervention: Nizatidine 300 mg hs
Number of subjects: 466
Study: 7236871

Group type: EXPERIMENTAL
Intervention: Propranolol 5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol 20-640 mg d-1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol (various doses)
Number of subjects: 17
Study: 30903276

Group type: EXPERIMENTAL
Intervention: Intraoperative indocyanine green (ICG) angiography
Number of subjects: 240

Group type: COMPARATOR
Intervention: Subjective visual evaluation of bowel perfusion without ICG (Control)
Number of subjects: 240
Study: 31235458

Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus-eluting stent (BP-SES)
Number of subjects: 575

Group type: COMPARATOR
Intervention: XIENCE Prime/Xpedition everolimus-eluting stent (PP-EES)
Number of subjects: 575
Study: 29121979

Group type: EXPERIMENTAL
Intervention: Ticagrelor (TIC) for 4 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ticagrelor plus Aspirin (TIC + ASP) for 4 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ticagrelor (TIC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ticagrelor plus Aspirin (TIC + ASP)
Number of subjects: 110
Study: 26194769

Group type: EXPERIMENTAL
Intervention: Diode laser surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scalpel surgery
Number of subjects: 0
Study: 23085863

Group type: EXPERIMENTAL
Intervention: Gadofosveset (0.03 mmol/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 35
Study: 21251179

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 0.1 to 12 mg, single escalating subcutaneous injections
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) doses ≥1.0 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) doses ≥3.0 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: LY2189265 (LY) during OGTT
Number of subjects: 6
Study: 19729238

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 103

Group type: COMPARATOR
Intervention: Suture
Number of subjects: 103
Study: 17593957

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 10 mg/kg, given once daily for 7 days
Number of subjects: 390

Group type: COMPARATOR
Intervention: Cefixime 20 mg/kg/day given in two divided doses for 7 days
Number of subjects: 390
Study: 15034229

Group type: EXPERIMENTAL
Intervention: Climodien 2/3 (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Estradiol valerate 2 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11511790

Group type: EXPERIMENTAL
Intervention: 100 ml of 20% human albumin followed by 160 mg of furosemide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham solution followed by 160 mg of furosemide
Number of subjects: 7
Study: 10990129

Group type: EXPERIMENTAL
Intervention: Waist circumference measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waist:hip ratio
Number of subjects: 0
Study: 7516361

Group type: EXPERIMENTAL
Intervention: Total paracentesis with dextran‐40 infusion (8 g per liter of ascitic fluid removed)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total paracentesis with dextran‐40 infusion
Number of subjects: 80
Study: 2660563

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times per day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice per day)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 83
Study: 30691746

Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercises (30 min, three sessions per week for six weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (usual daily activities)
Number of subjects: 20
Study: 29174216

Group type: EXPERIMENTAL
Intervention: AMP XR-OS under fasted conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMP XR-OS under fed conditions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference product under fed conditions
Number of subjects: 30
Study: 26561314

Group type: EXPERIMENTAL
Intervention: BAN (bananas)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PEAR (pears)
Number of subjects: 20

Group type: COMPARATOR
Intervention: WATER (control)
Number of subjects: 20
Study: 24032226

Group type: EXPERIMENTAL
Intervention: Combined systemic and regional chemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 70
Study: 21211103

Group type: EXPERIMENTAL
Intervention: Facemasks
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Intensified hand hygiene measures
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Facemasks and intensified hand hygiene
Number of subjects: 147
Study: 18721739

Group type: EXPERIMENTAL
Intervention: Chicken-based diet (CD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Enalapril (10 mg/day)
Number of subjects: 28
Study: 17002935

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation; specific dosage and duration not available
Number of subjects: 0
Study: 14586909

Group type: EXPERIMENTAL
Intervention: Progressive resistance strengthening exercises (9 lower-extremity exercises, 3 times a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physical therapy with resistance
Number of subjects: 0
Study: 11039742

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 188

Group type: COMPARATOR
Intervention: Betaxolol 0.25%
Number of subjects: 188
Study: 9526784

Group type: EXPERIMENTAL
Intervention: Names training group (n = 13)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo training group (n = 10)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Retest control group (n = 11)
Number of subjects: 34
Study: 8267700

Group type: EXPERIMENTAL
Intervention: Maintenance resistance training once a week
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maintenance resistance training twice a week
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups performing endurance training four times a week
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 4035232

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) alone or associated with conventional antihypertensive therapy
Number of subjects: 0
Study: 31168928

Group type: EXPERIMENTAL
Intervention: E-scale weight measurements
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: E-scale and clinic weight measurements taken on the same day
Number of subjects: 248
Study: 30021886

Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 therapy
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combination therapy (anti-CTLA-4 and anti-PD-1)
Number of subjects: 181
Study: 30641625

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 3 pills each time, 3 times per day for 3 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) Sulfate, 0.1 g per tablet, 2 tablets each time, twice per day for 3 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) Sulfate
Number of subjects: 58
Study: 24070401

Group type: EXPERIMENTAL
Intervention: Living cellular sheet (LCS; allogenic cultured keratinocytes and fibroblasts in bovine collagen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 0
Study: 22740509

Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day for 4 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20173020

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (1 mg/m²·d) for 12 and 24 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 85
Study: 17908978

Group type: EXPERIMENTAL
Intervention: LT plus ADV‐TK therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: LT only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LT plus ADV‐TK therapy (nonvascular invasion subgroup)
Number of subjects: 45

Group type: COMPARATOR
Intervention: LT only (nonvascular invasion subgroup)
Number of subjects: 45
Study: 15796730

Group type: EXPERIMENTAL
Intervention: Intravenous antivenom (AV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular antivenom (AV)
Number of subjects: 31
Study: 12443837

Group type: EXPERIMENTAL
Intervention: Ospemifene 25 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ospemifene 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ospemifene 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ospemifene 200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ospemifene (all doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9860407

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (3 MU thrice weekly) and ribavirin (1000-1200 mg/daily per os) for 24 weeks
Number of subjects: 303

Group type: COMPARATOR
Intervention: Interferon-alpha-2b alone (6 MU thrice weekly) for 24 weeks
Number of subjects: 303
Study: 8715357

Group type: EXPERIMENTAL
Intervention: Physiologic serum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non‐diluted hexetidine (Oraldine)
Number of subjects: 40
Study: 2571203

Group type: EXPERIMENTAL
Intervention: anti-Tac with CsA and prednisone
Number of subjects: 26

Group type: COMPARATOR
Intervention: cyclosporine CsA and prednisone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: anti-Tac with azathioprine and prednisone
Number of subjects: 26
Study: 31270676

Group type: EXPERIMENTAL
Intervention: AR/AI-guidance for trocar insertion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard fluoroscopy for trocar insertion
Number of subjects: 20
Study: 30361533

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (extremely randomized tree with adaptive boosting)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Experimental parameters optimization
Number of subjects: 330
Study: 27422421

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection (40 mg methylprednisolone) at monthly intervals for 6 consecutive months
Number of subjects: 230
Study: 26340806

Group type: EXPERIMENTAL
Intervention: Personally relevant items
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Generic items
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Generalization scripts (personally relevant)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Generalization scripts (generic)
Number of subjects: 8
Study: 23060056

Group type: EXPERIMENTAL
Intervention: Standard medical care plus chiropractic manipulative therapy (CMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 100
Study: 21903774

Group type: EXPERIMENTAL
Intervention: CYP3A4 T variant allele
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CYP3A4 T allele plus CYP3A5*3/*3
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CYP3A4 CC homozygotes plus CYP3A5*3/*3
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CYP3A4 T allele with CYP3A5*3/*3
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CYP3A4 CC homozygotes with CYP3A5*3/*3
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CYP3A4 T allele carriers with CYP3A5*1
Number of subjects: 185

Group type: COMPARATOR
Intervention: CYP3A4 CC homozygotes with CYP3A5*1
Number of subjects: 185
Study: 18582308

Group type: EXPERIMENTAL
Intervention: 15 mg/ml hyperbaric lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20 mg/ml hyperbaric lidocaine
Number of subjects: 100
Study: 16956334

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 125
Study: 12862201

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg daily (candesartan group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no candesartan)
Number of subjects: 52
Study: 10828634

Group type: EXPERIMENTAL
Intervention: 20% strontium nitrate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 8
Study: 9346162

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplement (N = 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (N = 13)
Number of subjects: 30
Study: 8475236

Group type: COMPARATOR
Intervention: Consult (1-month rotation on the Psychiatry Consultation Service)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liaison (31-hour workshops over 1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consult-plus-Liaison (both training programs experienced in consecutive years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2420164

Group type: EXPERIMENTAL
Intervention: Ethmozine (10 mg/kg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ethmozine (maintenance therapy)
Number of subjects: 13
Study: 31882387

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 91
Study: 30165051

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy screening (n = 20,552)
Number of subjects: 98684

Group type: COMPARATOR
Intervention: Control group (n = 78,126)
Number of subjects: 98684
Study: 24389520

Group type: EXPERIMENTAL
Intervention: Isometric fatiguing contraction (20% of maximal strength) with cognitive stress (difficult mental math task)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isometric fatiguing contraction (20% of maximal strength) with cognitive stress (simple mental math task)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Isometric fatiguing contraction (20% of maximal strength) with no mental task (control)
Number of subjects: 39
Study: 22715143

Group type: EXPERIMENTAL
Intervention: Short-foot exercise (SFE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Towel-curl exercise (TCE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both SFE and TCE
Number of subjects: 24
Study: 19243745

Group type: EXPERIMENTAL
Intervention: P along with 6 mg E(2) valerate vaginally (group C)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: P along with 6 mg E(2) valerate orally (group B)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Only P (group A)
Number of subjects: 270
Study: 18700216

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Antipsychotic medications (general)
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 1445
Study: 17171192

Group type: EXPERIMENTAL
Intervention: Intranasal insulin administration
Number of subjects: 0
Study: 14500057

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endometrial ablation (EA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hysterectomy and Endometrial ablation (EA)
Number of subjects: 0
Study: 9589972

Group type: EXPERIMENTAL
Intervention: Acupuncture (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment of RA using acupuncture (A)
Number of subjects: 0
Study: 7905890

Group type: EXPERIMENTAL
Intervention: Urias A‐4 closed drainage system
Number of subjects: 181

Group type: COMPARATOR
Intervention: Curity Infection Control System
Number of subjects: 181
Study: 3947490

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2.7 ml at L2/3 (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2 ml at L3/4 (Group D)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 ml at L3/4 (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2.7 ml at L3/4 (Group A)
Number of subjects: 40
Study: 31416450

Group type: EXPERIMENTAL
Intervention: Comprehensive sexuality education for 1 month, conducted by qualified midwives, with at least two sessions per week focusing on various aspects of sexual health and abstinence.
Number of subjects: 363

Group type: COMPARATOR
Intervention: Normal classes without additional intervention (control group).
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Comprehensive sexuality education for 1 month.
Number of subjects: 363

Group type: COMPARATOR
Intervention: Normal classes (control group).
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Health Belief Model (HBM).
Number of subjects: 363
Study: 28201994

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg once daily or 17.5 mg once weekly)
Number of subjects: 852
Study: 26066773

Group type: EXPERIMENTAL
Intervention: Thiamine (300 mg in 0.9% Normal saline solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.9% Normal saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiamine group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiamine supplementation
Number of subjects: 30
Study: 23177384

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 21733421

Group type: EXPERIMENTAL
Intervention: Subcutaneous local anesthetic mixture under the tourniquet
Number of subjects: 56

Group type: COMPARATOR
Intervention: No additional anesthetic
Number of subjects: 56
Study: 19812692

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid (PUFA) supplementation
Number of subjects: 0
Study: 16501712

Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant
Number of subjects: 514

Group type: COMPARATOR
Intervention: Standard water-handling practices
Number of subjects: 514
Study: 15163169

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2)
Number of subjects: 143
Study: 11710658

Group type: EXPERIMENTAL
Intervention: Lifting 90% of 1 repetition maximum (1RM) 5 times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifting 30% of 1 repetition maximum (1RM) 15 times
Number of subjects: 0
Study: 9054277

Group type: EXPERIMENTAL
Intervention: Screening for carotid disease with duplex Doppler ultrasonography
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1000
Study: 7506146

Group type: EXPERIMENTAL
Intervention: Nimesulide treatment for 7 to 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimesulide in combination with ambroxol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimesulide with concomitant antibacterial
Number of subjects: 0
Study: 3725477

Group type: EXPERIMENTAL
Intervention: Chest shielded with aluminum foil while on phototherapy (36 babies)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No shield (38 babies)
Number of subjects: 74
Study: 30105266

Group type: EXPERIMENTAL
Intervention: Biomarkers collected on the day of ACL reconstruction (specifically sf IL-1α, IL-1ra, MMP-9)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Biomarkers collected on the day of ACL reconstruction (specifically sf IL-1α)
Number of subjects: 22